Gilead Sciences to Present at Upcoming Investor Conferences
Get Alerts GILD Hot Sheet
Overall Analyst Rating:
BUY (= Flat)
Dividend Yield: 4.2%
Revenue Growth %: -0.6%
Join SI Premium – FREE
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
- BofA Securities 2021 Virtual Health Care Conference on Thursday, May 13, 2021 at 2:00 p.m. ET
- RBC Capital Markets 2021 Global Health Care Conference on Wednesday, May 19, 2021 at 10:20 a.m. ET
The live webcasts can be accessed at the company’s investors page at investors.gilead.com. The replays will be available for at least 30 days following the presentation.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210506006218/en/
Jacquie Ross, Investors
(650) 358-1054
Source: Gilead Sciences, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Almonty Closes Additional Tranches of Private Placement
- Statement on behalf of the Maher Family
- ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages CI&T Inc Investors to Inquire About Securities Class Action Investigation – CINT
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
RBC Capital, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!